NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT07146646 2026-02-19
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT07025174 2025-06-17
SAIB
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT05712356 2025-06-06
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Active not recruiting
NCT03111732 2021-12-03
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01229111 2017-03-29
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01572324 2017-01-04
Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas
Peking University
Phase 2 Completed
NCT00338988 2012-08-01
Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma
M.D. Anderson Cancer Center
Phase 2 Completed